[Active surveillance: current status and future perspectives].
Widespread use of PSA testing has resulted in decrease in prostate cancer mortality but increase in clinically indolent prostate cancer. Active surveillance (AS) is an important strategy to reduce prostate cancer overtreatment. However, the optimal criteria for eligibility and predictors of biopsy reclassification remain to be debated. Due to inadequate reliability of PSA-kinetics including PSA-doubling time during AS, repeated biopsy is indispensable for every AS program. To reduce physical and psychological burden associated with repeated biopsy, studies on the clinical usefulness of mpMRI and new biomarkers in AS program are warranted.